Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Cogent Biosciences, Inc.

Market Cap 6.13B 5.38B 4.96B 4.64B 8.7B 580B 8.84B 59.54B 23.05B 285B 23B 22.5B 990B P/E 2026 *
-15.7x
P/E 2027 * -43.4x
Enterprise Value 6.07B 5.33B 4.91B 4.6B 8.62B 575B 8.76B 59B 22.84B 282B 22.79B 22.3B 981B EV / Sales 2026 *
642x
EV / Sales 2027 * 17.6x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
06-12 Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial MT
06-12 Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology CI
06-12 Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis CI
05-30 Cogent Biosciences announces detailed clinical data from peak phase 3 trial with bezuclastinib in combination with sunitinib RE
05-30 Cogent Biosciences, Inc. Announces Detailed Clinical Data From PEAK Phase 3 Trial With Bezuclastinib In Combination With Sunitinib In Gastrointestinal Stromal Tumors CI
05-28 Cogent Says FDA Accepts NDA for Bezuclastinib Combination MT
05-28 Cogent Biosciences Announces Fda Acceptance of New Drug Application with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with Gist CI
05-05 Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-17 Cogent Biosciences Announces Poster Presentations At the American Association for Cancer Research Annual Meeting 2026 CI
04-01 Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors in US MT
04-01 Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors CI
03-16 Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis CI
03-16 Cogent Biosciences Says FDA Accepted Marketing Application for Bezuclastinib in Non-Advanced Systemic Mastocytosis MT
1 day+2.26%
1 week+10.04%
Current month+4.09%
1 month+7.22%
3 months+2.77%
6 months-9.41%
Current year+2.45%
1 week 32.95
Extreme 32.95
36.55
1 month 30.93
Extreme 30.93
36.55
Current year 30.87
Extreme 30.87
41.35
1 year 6.94
Extreme 6.94
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 2020-10-22
Director of Finance/CFO 45 2018-05-31
Chief Tech/Sci/R&D Officer 52 2021-04-05
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Director/Board Member 74 2019-07-25
Director/Board Member 59 2019-07-25
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

17,901 0.0105%
06-08Free

Director

17,901 0.0105%
06-08Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+10.04%+401.24%+200.99% 6.13B
+2.14%+7.57%+74.46%+123.84% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+1.16%+1.85%-11.51%-14.92% 22.81B
+3.77%+7.61%-2.49%+414.98% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+9.80%+26.27%-34.74% 15.56B
+0.53%-0.95%+18.99%+159.84% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
Average +1.53%+2.37%+75.58%+130.48% 22.36B
Weighted average by Cap. +1.40%+3.31%+55.73%+116.88%

Financials

2026 *2027 *
Net sales 9.46M 8.31M 7.66M 7.17M 13.43M 896M 13.66M 91.96M 35.6M 440M 35.52M 34.75M 1.53B 345M 303M 280M 262M 490M 32.71B 499M 3.36B 1.3B 16.05B 1.3B 1.27B 55.78B
Net income -392M -344M -317M -297M -556M -37.09B -565M -3.81B -1.47B -18.2B -1.47B -1.44B -63.26B -134M -118M -109M -102M -190M -12.7B -194M -1.3B -504M -6.23B -503M -492M -21.66B
Net Debt -55.22M -48.51M -44.7M -41.84M -78.4M -5.23B -79.72M -537M -208M -2.57B -207M -203M -8.92B -63.88M -56.11M -51.71M -48.4M -90.69M -6.05B -92.22M -621M -240M -2.97B -240M -235M -10.32B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
26-06-23 US$36.43 +1.63% 2,195,072
26-06-22 US$35.84 +3.76% 3,175,459
26-06-18 US$34.54 +2.58% 4,898,257
26-06-17 US$33.67 +1.81% 2,067,975
26-06-16 US$33.07 -0.30% 1,603,105
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
35.84USD
Average target price
54.25USD
Spread / Average Target
+51.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!